In addition, a Phase I clinical trial of AL002 (NCT03635047) found the antibody to be safe and tolerable in healthy adults with mild-to-moderate AD, and the levels of TREM2 in CSF were found to be decreased in a dose-dependent fashion after a single intravenous injection of AL002. This evidence concerns the gene TREM2 and Alzheimer disease.